Fig. 4: HDAC6 overexpression correlates with poor prognosis in EWS patients, and in vivo combined treatment reduces EWS tumor growth. | Oncogene

Fig. 4: HDAC6 overexpression correlates with poor prognosis in EWS patients, and in vivo combined treatment reduces EWS tumor growth.

From: Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma

Fig. 4

A, B HDAC6 Kaplan–Meier plot with OS and DFS, according to the transcript. IHC expression in primary EWS tumor samples showed statistically significant differences between low- and high-HDAC6-expressing tumors in two independent series (series 1 and 2). C Tumor growth was monitored in A673 and HSJD-ES-001 xenografts models after single-agent or combination therapies. Tumor volumes (mm3) were measured after 15 days (A673) or 21 days (HSJD-ES-001) of treatment. D Quantification of Ki67-high positively-labeled nuclei percentage after 15 or 21 days of treatment. E Anatomopathological quantification of FLI1 expression after 15 or 21 days of treatment, with three levels of expression threshold set: low, medium, and high. F Immunohistochemical staining of FLI1 in xenograft tumor samples treated with ACY-1215 and doxorubicin, alone or in combination (40× magnifications). *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page